Talk Clinical Strategy track
Before the Deal: What Western Buyers Must Resolve About China-Origin Evidence and Policy Risk
Tue, Nov 10, 2026 · 9:30–9:45 AM CET Clinical Strategy Stage, Koelnmesse
About this session
Identify evidence gaps that could affect European development and market access, and the questions Western buyers should resolve with clinical, regulatory and HTA specialists before committing. Assess whether China-origin clinical data meets European regulatory standards, identify critical evidence gaps, and determine what bridging studies or additional trials are required to support your regulatory and market-access strategy Understand how data ownership rights, ongoing reliance on China-based CROs or trial sites, and regulatory responsibilities impact your clinical development timeline,…
